Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765340 | 0.93 | S1PR1 (1.00) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2772770 | 0.91 | S1PR1 (0.93) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2771674 | 0.89 | S1PR1 (1.00) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3763969 | 0.88 | S1PR1 (1.00) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3761536 | 0.88 | S1PR1 (1.00) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3766598 | 0.85 | S1PR1 (0.84) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2773198 | 0.84 | S1PR1 (0.80) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2775237 | 0.83 | S1PR1 (0.88) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3759437 | 0.83 | S1PR1 (0.85) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL2771501 | 0.83 | S1PR1 (1.00) | S1PR1RAB9ASMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| EP-2193126-B1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO SA (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889668-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-8404676-B2 | Oxadiazole diaryl compounds | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | MERCK SERONO SA | 2010-12-02 | — | — | US | disclosed |
| WO-2009043890-A1 | OXADIAZOLE DIARYL COMPOUNDS | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305104-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | S1PR1 277/4885RAB9A 1744/4885SMN1; SMN2 1480/4885 |
| US-20130109676-A1 | Oxadiazole Diaryl Compounds | OXA1L, RO60, SSB | S1PR1 174/4885RAB9A 1833/4885SMN1; SMN2 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.